Improving medication adherence and blood pressure control in older African Americans
OPtimizing Technology to Improve Medication Adherence and Blood Pressure Control
This study is testing a new technology-based program to help older African Americans better manage their high blood pressure and improve their overall health.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 208 (estimated) |
| Ages | 50 Years and up |
| Sex | All |
| Sponsor | Case Western Reserve University Academic / other |
| Locations | 1 site (Cleveland, Ohio) |
| Trial ID | NCT05293756 on ClinicalTrials.gov |
What this trial studies
OPTIMA-BP is an interventional study that evaluates a technology-based approach to enhance self-management of hypertension among older African Americans. The study involves a 12-month randomized control trial comparing the intervention group with a waitlist control group, focusing on systolic blood pressure and health-related quality of life. It also examines the role of knowledge, self-efficacy, and social support in managing hypertension. Qualitative evaluations will be conducted to identify barriers and strengths of the intervention for future improvements.
Who should consider this trial
Good fit: Ideal candidates are African American individuals aged 50 and older who have hypertension and are prescribed multiple antihypertensive medications.
Not a fit: Patients who have experienced a major cardiovascular event in the past year or have chronic kidney disease may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to better blood pressure control and improved quality of life for older African Americans with hypertension.
How similar studies have performed: Other studies have shown promise in using technology for hypertension management, indicating that this approach may be effective.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Self-identify as African American 2. 50 years of age or older 3. Diagnosed with hypertension, with a systolic blood pressure≥ 130 mmHg but less than 170 mmHg 4. Prescribed at least two hypertensive, one of which is a diuretic/thiazide and or calcium channel blocker antihypertensive medication 5. Own a smartphone with a data plan, the capability to download the Medisafe app, or view videos 6. Able to read/understand English Exclusion Criteria: 1. Unable to give informed consent or judged to have impaired cognitive ability or severe memory 2. Currently using a medication management application (app) 3. Experienced a major CVD event or procedure (e.g., myocardial infarction, stroke, heart surgery) within the past year 4. Patients with a diagnosis of chronic kidney disease (defined as estimated glomerular filtration rate (eGFR) \< 60 ml/min/1.73m2) and/or receiving dialysis.
Where this trial is running
Cleveland, Ohio
- Case Western Reserve University — Cleveland, Ohio, United States (Recruiting)
Study contacts
- Principal investigator: Carolyn Still, PhD — Case Western Reserve University, School of Nursing
- Study coordinator: Carolyn Still, PHD
- Email: carolyn.still@case.edu
- Phone: 216-368-6338
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.